Maintaining Hold: The Reset Held and the Third Cut Didn't Come — But a $1-of-Below-the-Line "Beat" and a 2026 Management Calls "the Trough" Mean the Recovery Still Can't Be Underwritten
Key Takeaways
- An "in-line" quarter dressed as a beat. Adjusted EPS of $6.03 cleared the $4.95 Street number by ~$1.08, but management itself attributes ~$1 to below-the-line tax timing and investment-income gains, and pegs $27 — not $30 — as the clean FY earnings baseline excluding ~$3 of nonrecurring items. The reaffirmed ~$30 held, which matters (no third cut), but the underlying operating quarter was merely consistent with July's reset.
- The benefit ratio keeps climbing and Medicaid is now loss-making. The consolidated MLR rose to 91.3% (from 88.9% in Q2), and management now expects FY2025 Medicaid operating margin to be modestly negative (~−50bps). Health Benefits segment margin was just ~1.4%, implying the government book is running below breakeven.
- 2026 was pre-framed as a down year. Management laid out planning assumptions — Medicaid operating margin down at least 125bps YoY, ~$1 of EPS from incremental strategic investment, MA service-area exits (~150K members), and a potential ACA membership cliff if enhanced subsidies expire — and explicitly called 2026 "the trough," with 2027 a "return to balanced growth." No formal 2026 guide until January.
- The franchise levers still work. Carelon Rx revenue grew 20% and Carelon Services >50%; MA margins are now expected to improve slightly in 2025 with Stars stepping up (≈55% of members in 4-star-plus contracts for PY2027 vs. ≈40% for PY2026); and the buyback ramped to $875M from ~$380M in Q2. The diversification and quality engines are intact beneath the Medicaid drag.
- Rating: Maintaining Hold. The reset's durability lowers third-cut risk and the de-rating is largely spent, but with 2026 shaping up as a trough year, formal guidance withheld until January, and the ACA subsidy outcome unresolved, there is no catalyst to upgrade today. The January Q4 print — when the trough is finally quantified — is the decision point. We stay constructive-but-sidelined.
Results vs. Consensus
Q3 2025 Scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Operating Revenue | $50.1B | ~$49.3B | Beat | +~1.5% |
| Adjusted EPS (reported) | $6.03 | ~$4.95 | Beat | +$1.08 |
| Adjusted EPS (ex ~$1 below-the-line) | ~$5.00 | ~$4.95 | In line | ~flat |
| GAAP Diluted EPS | $5.32 | n/a | — | — |
| Consolidated Benefit Expense Ratio (MLR) | 91.3% | ~91.0% | In line | +~30bps |
| Adj. Operating Expense Ratio | 10.4% | ~10.4% | In line | ~flat |
| Medical Members | 45.4M | ~45.5M | Slightly light | −~200K QoQ |
| FY2025 Adj. EPS Guide | ~$30 (reaffirmed) | ~$30 | Held | — |
Year-Over-Year Comparisons
| Metric | Q3 2025 | Q3 2024 | Change |
|---|---|---|---|
| Operating Revenue | $50.1B | $44.7B | +12.0% |
| Adjusted EPS | $6.03 | $8.37 | −28.0% |
| Benefit Expense Ratio | 91.3% | 89.5% | +180bps |
| GAAP Diluted EPS | $5.32 | $4.36 | +22.0% |
| Medical Membership | 45.4M | ~45.8M | −~0.9% |
Context: the Q3 2024 comp was itself a guidance-cut quarter — ELV cut FY2024 adjusted EPS to ~$33 (from ~$34.05) in October 2024 on the same Medicaid rate-acuity mismatch. So the −28% YoY adjusted-EPS decline is measured against an already-impaired base, underscoring that this is a multi-year cycle, not a single bad year. The GAAP-EPS increase YoY is a function of much smaller acquisition/amortization adjustments in the current quarter, not operating improvement.
Quarter-Over-Quarter Comparisons
| Metric | Q3 2025 | Q2 2025 | Change |
|---|---|---|---|
| Operating Revenue | $50.1B | $49.4B | +1.4% |
| Adjusted EPS | $6.03 | $8.84 | −31.8% |
| Benefit Expense Ratio | 91.3% | 88.9% | +240bps |
| FY25 Adj. EPS Guide | ~$30 (reaffirmed) | ~$30 (reset) | Held |
Q3 is structurally the highest-MLR quarter of the managed-care year, so a meaningful share of the 240bps QoQ benefit-ratio rise is seasonal. The signal is that the ratio came in at management's expectation rather than above it — the first quarter in a while where the company did not have to revise downward.
Quality of Beat/Miss
- Revenue: The ~$0.7B revenue beat is again premium-yield- and acquisition-driven — repricing for cost trend plus the home-health/pharmacy deals — not organic membership strength. Medicaid reverification continues to shrink the member base (45.4M, down ~200K QoQ).
- EPS: Low quality. Of the $1.08 beat versus consensus, management attributes roughly $1 to (a) the timing of planned tax actions and (b) ~$150M of discrete valuation gains in the alternatives investment portfolio (net investment income of $625M). The clean operating print was ~$5, essentially in line. The voluntary "$27 baseline" disclosure is the company telling you to model the lower number.
- Margins: The 91.3% benefit ratio landing in line with plan is genuinely the good news — for the first time in this cycle, the medical-cost line did not surprise to the downside. But "in line with a reset plan" is a low bar, and Medicaid turning outright loss-making (~−50bps FY operating margin) shows the absolute level of pressure is still intensifying even as the rate of negative surprise slows.
Segment Performance
| Segment | Trend | FY2025 Margin Read | 2026 Setup |
|---|---|---|---|
| Medicaid (within Health Benefits) | Pressured | ~−50bps operating margin (loss-making) | Down ≥125bps YoY; "the trough" |
| Medicare Advantage | Stabilizing | Slight margin improvement in 2025 | Disciplined bids; ~150K member exits; Stars step-up |
| ACA / Individual | Less-bad | High-single-digit operating-margin decline | Repriced; membership cliff risk on subsidy expiry |
| Commercial Group | In line | Largely consistent with prior expectations | Strong retention; fee-based expansion |
| CarelonRx | Strong | Revenue +20%; margin modestly below guide (investment) | National-account wins; specialty migration |
| Carelon Services | Strong | Revenue +>50%; toward high end of guide | External growth; Health Benefits membership headwind |
Medicaid — now loss-making, and the entire 2026 story
Medicaid is where the cycle lives. Management now expects the FY2025 Medicaid operating margin to be modestly below breakeven (~−50bps), with disenrollment continuing to concentrate among lower-acuity members under stricter eligibility reviews — mechanically raising the acuity of those who remain. The 2026 planning assumption is a further decline of at least 125bps, anchored to the Q4 2025 exit rate (the seasonal margin low), against a long-term 2–4% target.
"We now expect our full year 2025 Medicaid operating margin to be modestly negative... establishing a baseline from which we anticipate a decline of at least 125 basis points in 2026 as rates continue to lag acuity and utilization trends remain elevated." — Mark Kaye, CFO
Assessment: A loss-making Medicaid book guiding to a deeper loss next year is the crux of why this is still a Hold. The offset is management's unusually firm "2026 is the trough" language and the four concrete recovery levers (care management, OBBBA pacing, rate catch-up, prudent base). But "trough" is a forecast, not a result — and the same team forecast two prior years that proved too optimistic.
Medicare Advantage — quietly the bright spot
Against the Medicaid drag, MA is the segment turning the right way: trend was marginally better than expected, management now expects the 2025 operating margin to improve slightly (versus prior "stable"), and the Stars trajectory is genuinely strong — roughly 55% of MA members will be in 4-star-or-higher contracts for payment year 2027 (including three 5-star contracts), up from about 40% for PY2026. The 2026 posture is margin-first: disciplined bids, exited service areas affecting ~150K members, and a deliberate HMO/D-SNP concentration.
"For the 2027 payment year, approximately 55% of our MA members will be in 4-star or higher contracts, including three 5-star contracts, up from about 40% for payment year 2026." — Gail Boudreaux, CEO
Assessment: This is the most underrated disclosure in the release. The Stars step-up is a real, dollar-quantifiable 2027 tailwind (rebate dollars and bonus payments), and ELV is executing margin discipline in MA precisely while several peers are stumbling. It is the clearest evidence that the franchise's controllable levers are working.
Carelon — external growth keeps compounding
Carelon Rx grew revenue 20% on national-account wins and specialty-pharmacy migration (BioPlus/Kroger Specialty scripts transitioning), and Carelon Services grew >50%, trending toward the high end of its guide on CareBridge integration and external-client expansion. Management flagged that 2026 Health Benefits membership losses will create a directional headwind for Carelon (Elevance is its largest client), but framed it as time-bound against strong external momentum.
"Carelon Rx revenue grew 20% year-over-year... and Carelon Services grew by more than 50%, supported by robust organic growth and the continued integration of CareBridge." — Mark Kaye, CFO
Assessment: Carelon remains the structural reason to own ELV through the cycle. The 2026 membership headwind is real but transitory; the external-revenue growth (double digits) is the proof the platform is not merely an internal cost center. This is the engine that should re-accelerate enterprise growth in 2027.
Key KPIs
| KPI | Q3 2025 | Q2 2025 | Trend | Read |
|---|---|---|---|---|
| Medical members | 45.4M | 45.6M | ↓ | Medicaid reverification continues |
| Benefit expense ratio | 91.3% | 88.9% | ↑ (seasonal + trend) | In line with plan — the good news |
| Adj. operating expense ratio | 10.4% | 10.0% | ↑ | Investment ramp beginning |
| Days in claims payable (ex-CareBridge) | 42.6 | ~43 | → (flat YoY) | No reserve-quality red flag |
| Net investment income | $625M | — | ↑ | ~$150M discrete valuation gains (one-time) |
| Operating cash flow | $1.1B | $2.1B | ↓ | BCBS MDL settlement payment |
| Buyback | $875M | $380M | ↑ | Ramped — confidence signal |
Key Topics & Management Commentary
Overall Management Tone: The posture shifted from Q2's accountability-and-apology to a more composed, forward-leaning stance built around two refrains: results came in "consistent with the outlook we shared last quarter," and 2026 is "the trough" before a 2027 recovery. Management was noticeably more willing to pre-commit to a directional 2026 framework — naming the Medicaid −125bps, the ~$1 investment headwind, and the MA exits — even while withholding a formal EPS number until January, which reads as a deliberate effort to control the narrative rather than be forced into another reset. The least convincing thread remained timing: every recovery claim was anchored to "January visibility" or "2027," never to a result already in hand.
1. The Reaffirm and the $27 Baseline
The headline action is the reaffirmation of ~$30 FY2025 adjusted EPS — the first quarter in this cycle without a downward revision. But management paired it with an unusually explicit modeling instruction: treat $27 as the clean baseline, because ~$30 includes ~$3 of discrete nonrecurring items (tax actions, the Q2 value-based-care settlement, and investment-income valuation gains).
"We are reaffirming 2025 adjusted EPS of approximately $30 and continue to view $27 as the appropriate earnings baseline, excluding $3 of discrete nonrecurring items." — Gail Boudreaux, CEO
Assessment: Telling the Street to model $27 rather than $30 is candor that cuts both ways: it rebuilds trust (no hiding the ball) but resets the 2026 jumping-off point ~10% below the headline. Any 2026 growth must be measured from $27, not $30 — a subtlety that will define whether next year's number "grows" or "declines" in the market's eyes.
2. Benefit Ratio at 91.3% and Medicaid Below Breakeven
The consolidated benefit ratio of 91.3% landed in line — the first non-negative MLR surprise of the cycle — but the composition is stark: Medicaid is now expected modestly negative for the full year, and the Health Benefits segment margin was just ~1.4%, implying the government book overall is at or below breakeven, masked by a profitable commercial book.
"The consolidated benefit expense ratio was 91.3%, aligned with our expectations. Medicaid performance reflected pressure from elevated acuity and utilization, which were not fully offset by rate updates." — Mark Kaye, CFO
Assessment: "In line" is real progress on the rate of deterioration but says nothing about the level, which is still worsening. A loss-making Medicaid book is the definition of a fixable-but-not-yet-fixed problem; the in-line MLR is necessary but not sufficient for an upgrade.
3. The Medicaid 2026 Bridge: −125bps and "the Trough"
Management's central 2026 planning input is a Medicaid operating-margin decline of at least 125bps, split roughly evenly between rates continuing to lag acuity and persistently elevated utilization. Crucially, management framed 2026 as the low point — "the trough, not the beginning of another reset period" — with sequential improvement expected through 2027 toward the 2–4% target range.
"We do view 2026 as the trough, not the beginning of another reset period. And the actions we are taking will position us to improve through the cycle as we ultimately target that 2% to 4% margin range over time." — Mark Kaye, CFO
Assessment: The "trough" call is the single most important forward statement of the quarter — if credible, it implies a datable bottom and turns ELV into a forward-looking recovery story. We give it qualified weight: the anchoring to the Q4 exit rate (the seasonal low) is methodologically conservative, but the same management forecasting framework underestimated 2024 and 2025.
4. The ~$1 Investment Headwind into 2026
On top of Medicaid, management flagged several hundred million dollars — roughly $1 of EPS — in incremental 2026 strategic investment across three buckets: AI/technology adoption (clinical workflows, automation, core-system modernization), Carelon scaling (up-market onboarding, pharmacy capabilities), and operational/quality initiatives (Stars, member engagement). Management characterized these as front-loaded investments to set up 2027 operating leverage.
"We do expect to make discrete investments worth several hundred million dollars and quantify that as approximately $1 of EPS really to advance our strategic goals... we see these as front-loaded investments." — Mark Kaye, CFO
Assessment: Self-inflicted but strategically defensible. A $1 EPS investment drag on top of a Medicaid trough means 2026 is mathematically very likely a down year off the $27 baseline. The bet is that 2027 leverage justifies the 2026 dilution — a reasonable bet, but one that asks shareholders to look through a second straight year of pressure.
5. The ACA Subsidy Cliff
The largest exogenous swing factor for 2026 is the scheduled expiration of the enhanced ACA premium tax credits. Management's filings already reflect higher acuity and a smaller market, but if the subsidies lapse, it expects a material contraction in exchange membership and an even more acute residual risk pool, citing CBO estimates of meaningfully lower enrollment.
"If the enhanced advanced premium tax credits were to expire at year-end, we'd expect a material contraction in the ACA marketplace... that smaller, more acute pool does mean fewer enrollees to spread risk and sharper premium increases." — Mark Kaye, CFO
Assessment: A binary the company cannot control and would not size in its own membership terms. Counterintuitively, a smaller, repriced ACA book could be better for margin even as it shrinks revenue — but the transition year (2026) carries the disruption. This is the cleanest example of why a 2026 number is genuinely un-guidable today.
6. State Negotiations: Rates Plus Program Changes
A meaningful tonal shift this quarter: state conversations have broadened from rates alone to program design. With the enhanced FMAP gone and Medicaid among the largest line items in state budgets, states are now receptive to benefit refinements — applied behavioral analysis (ABA), GLP-1 management, site-of-care optimization — that reduce program cost rather than relying solely on rate increases.
"States are certainly more receptive to ways that can help reduce the overall cost of the Medicaid program and improve affordability... the conversations this time around have certainly not just been about rates." — Felicia Norwood, President, Government Health Benefits
Assessment: Constructive and underappreciated. Program-design levers give ELV a second path to Medicaid margin recovery that does not depend solely on the rate-cycle lag — and aligns its Carelon care-management capabilities with state cost goals. It is slow-moving (changes align to contract years) but structurally favorable.
7. Capital Allocation: Buyback Ramps to $875M
ELV repurchased $875M of stock in Q3, a sharp step-up from ~$380M in Q2, signaling restored confidence after the Q2 flexibility pause. Management reiterated the integrate-don't-acquire posture (focus on absorbing the Carelon M&A of prior years) and prioritized buybacks within the capital-return framework.
"In the quarter, we repurchased $875 million of shares, reflecting our disciplined approach to capital deployment and commitment to returning value to shareholders even as we continue integrating recent acquisitions." — Mark Kaye, CFO
Assessment: The buyback ramp is a more convincing confidence signal than Q2's slowed pace, and at a de-rated multiple it is accretive. It also reflects the M&A pause freeing cash for repurchase. A constructive data point, though not enough on its own to change the rating.
8. The 2027 "Balanced Growth" Bridge
Management's framing of 2027 as a "return to a more balanced earnings growth profile" rests on four drivers: improved Medicaid rate alignment, further MA margin normalization (aided by Stars), sustained Carelon momentum, and the operating leverage from 2026's front-loaded investments. Importantly, management quantified the OBBBA reverification impact as hitting less than 20% of ELV's Medicaid membership in 2027, with provisions staggered into 2027–2028.
"While we're not providing an out-year EPS growth rate today... past 2026, the business should again resemble that more balanced, consistent growth that we've historically delivered." — Mark Kaye, CFO
Assessment: The 2027 bridge is logically coherent and the <20%-membership OBBBA sizing is reassuring against the bear fear of a second redetermination-scale shock. But it is a two-years-out promise built on multiple variables resolving favorably. We credit the direction, not yet the magnitude.
Guidance & Outlook
| Metric | Prior (Q2 2025) | Current (Q3 2025) | Change |
|---|---|---|---|
| FY2025 Adjusted EPS | ~$30 | ~$30 (reaffirmed) | Held (no third cut) |
| FY2025 Clean Baseline | (implied) | ~$27 (ex ~$3 nonrecurring) | Newly disclosed |
| FY2025 Benefit Expense Ratio | ~90% | ~90% | Maintained |
| FY2025 Medicaid Operating Margin | Positive, below target | Modestly negative (~−50bps) | Lowered |
| FY2026 Adjusted EPS | Not given | Not given (Jan) | Inputs framed: trough year |
| FY2026 Medicaid margin | — | Down ≥125bps YoY | New planning input |
Management deferred formal 2026 guidance to the January Q4 call, citing the need for visibility on January Medicaid rate resets, Medicare AEP results, the enhanced-subsidy outcome, and the remainder of the year's cost trends. In the interim it provided enough directional inputs — Medicaid −125bps, ~$1 investment drag, MA exits, ACA cliff risk — to make clear that 2026 will be a down/trough year measured against the $27 baseline.
Implied 2026 math: A $27 clean 2025 base, less ~$1 of incremental investment and the Medicaid margin step-down, partly offset by Carelon growth, MA stabilization, and buyback — triangulates to a 2026 number plausibly in the high-$20s, i.e., roughly flat-to-down. Management would not confirm this, which is precisely the point.
Street at: Consensus will spend the next quarter migrating its 2026 estimates down toward the trough framing; the muted stock reaction suggests much of this was already discounted.
Guidance style: The deliberate withholding of a 2026 number — while pre-seeding the negative inputs — is a credibility-management strategy: lower the bar verbally now, guide formally to an achievable number in January, and avoid a fourth surprise. Disciplined, if frustrating for modelers.
Analyst Q&A Highlights
Whether states acknowledge the Medicaid pressure, and where the pain is concentrated
The opening question pressed on whether state partners accept the severity of the cost trend, whether the problem is worse trend or lagging rates, and whether contemplated benefit-design changes represent upside. Management split the answer — the CFO framed the two anchors (trend and rates) behind the at-least-125bps decline and disclosed the ~−50bps FY2025 Medicaid margin; the government-benefits head emphasized newly constructive, program-design-oriented state conversations.
Q: "When you're in your dialogue with the states, are they acknowledging that?... Is it just the cost trend is worse than you would have anticipated... Is it the rate updates are not coming in as you thought? And are you factoring in any of this change in benefit design... Or would that be potentially upside?"
— A.J. Rice, UBS
A: "We now expect the full year 2025 Medicaid operating margin to be modestly below breakeven or approximately negative 50 basis points... We do view 2026 as the trough, not the beginning of another reset period... we ultimately target that 2% to 4% margin range over time." — Mark Kaye, CFO
Assessment: The most complete answer of the call, and the source of the "trough" anchor. Management both owned the loss-making present and committed to a datable bottom — the program-design optionality is genuine incremental upside not yet in the numbers.
Whether the 2026 investment spend is transitory
A recurring line of questioning sought to understand the materiality and durability of the flagged incremental investment, and whether it is the reason 2027 earnings growth is constrained. Management quantified it at ~$1 of EPS across technology, Carelon scaling, and quality/Stars, and characterized it as front-loaded — a 2026 cost to build 2027 operating leverage.
Q: "You're talking about potentially several hundred million dollars of investments... trying to understand what you guys are trying to spike there in terms of materiality to 2026... Is it fair to think that some of this increased investment is transitory in nature?"
— Stephen Baxter, Wells Fargo
A: "We do expect to make discrete investments worth several hundred million dollars and quantify that as approximately $1 of EPS... technology adoption... Carelon investments... operational and quality initiatives... we see these as front-loaded investments across the board." — Mark Kaye, CFO
Assessment: Useful quantification — it converts a vague "investment" into a modelable ~$1 headwind. "Front-loaded" implies it does not recur at the same scale in 2027, supporting the leverage story, but it also confirms 2026 carries a self-inflicted drag on top of the Medicaid cycle.
ACA membership if the enhanced subsidies expire
An analyst pressed for the membership delta under a no-extension scenario. Management declined to size its own book but confirmed it expects a material marketplace contraction and a sharply more acute residual pool, leaning on CBO estimates and emphasizing its filings are prepared for a range of policy outcomes.
Q: "Can you give us any color around what the difference would be in membership as we think about '26, should they... not have the enhanced subsidies in '26... really just the question is really around membership."
— Lisa Gill, JPMorgan
A: "If the enhanced advanced premium tax credits were to expire at year-end, we'd expect a material contraction in the ACA marketplace... independent estimates from the Congressional Budget Office... indicate meaningfully lower enrollment and a much higher morbidity risk pool into 2026." — Mark Kaye, CFO
Assessment: Management's refusal to put its own number on the ACA membership cliff is appropriate given the policy uncertainty but leaves a large unmodelable hole in 2026. The silver lining — a repriced, smaller book can carry better margins — is the bull's escape hatch, but the transition disruption is the bear's near-term point.
The Medicaid Q4 exit run-rate versus the 125bps planning figure
A pointed exchange noted that with Medicaid deteriorating through the year, the Q4 run-rate margin is likely worse than the ~−50bps full-year average, and asked how the at-least-125bps 2026 decline relates to that exit rate. Management confirmed the premise and clarified that 2026 is planned off the Q4 exit (the seasonal low), reinforcing the prudence of the base.
Q: "This business has deteriorated through the year, and thus, the losses are probably more significant... the run rate in 3Q and 4Q might be worse than that minus 50 basis points annually... how that 125 basis points compares to that Q4 run rate?"
— Justin Lake, Wolfe Research
A: "Your underlying premise is correct. Margins deteriorated as the year has gone on... we are assuming that we enter the year at the place we exited the year... that's really why we see 2026 as the low point in the Medicaid margin." — Mark Kaye, CFO / Gail Boudreaux, CEO
Assessment: This exchange did the most to validate the "trough" framing methodologically — planning 2026 off the worst quarter of 2025 is genuinely conservative. It is the strongest technical argument that the 125bps is a real floor-ish input rather than another optimistic anchor.
Whether 2027 returns to the full growth algorithm, and reconciliation-bill pull-forward risk
An analyst asked whether the reconciliation bill's risk-pool shifts could be pulled forward into 2026, and whether "balanced growth" in 2027 means the full long-term algorithm or something less. Management sized the OBBBA reverification at <20% of Medicaid membership (staggered to 2027–2028) and described 2027 as a return to the historical multi-segment growth algorithm.
Q: "There's been a concern that the risk pool shifts that are supposed to happen from the reconciliation bill could be pulled forward... when you guys talked about returning to balanced growth in 2027, is that... back to the normal growth algorithm? Or is balance kind of imply something a little bit less?"
— Kevin Fischbeck, Bank of America
A: "When we talk about that return to a more balanced earnings growth profile in 2027, we really need getting back to the growth algorithm that has characterized our business... contributions from Commercial, government, Carelon, supported by the operating leverage and disciplined capital deployment." — Mark Kaye, CFO
Assessment: The <20%-membership OBBBA sizing directly rebuts the "second redetermination shock" bear case and is the most reassuring policy disclosure of the call. "Balanced growth = the historical algorithm" sets a real, if unquantified, 2027 expectation that anchors the recovery thesis.
Reconciling 2027 recovery with another OBBBA-driven acuity shift
A skeptical follow-up questioned how Medicaid margins can sequentially improve through 2027 if OBBBA triggers a fresh acuity shift starting late 2026 — another lag between acuity and rate catch-up. Management walked through the four 2027 recovery drivers and reiterated that the bill's reverification touches less than 20% of members and is staggered, limiting the shock.
Q: "OB3 will trigger another round of acuity shift maybe starting as early as late '26... I'm trying to marry that with your expectations for sequential improvement in Medicaid margin through '27 when you are facing what seems like another acuity shift ahead of rate catch-up."
— David Windley, Jefferies
A: "It is not complete reverification. It's less than 20% of our membership will be impacted... federal changes under the bill they are going to be staggered primarily effective in '27 and '28... that pacing then reduces execution risk and supports a more steadier transition of the risk pool." — Mark Kaye, CFO / Gail Boudreaux, CEO
Assessment: A direct, quantified rebuttal to the most important bear concern. If the <20%-staggered framing holds, the 2027 recovery survives the OBBBA overlay; if it proves optimistic, the trough slips to 2027 and the whole recovery timeline moves right. This is the variable we will track most closely.
What They're NOT Saying
- A 2026 EPS number — even a range. Deferred to January. Management pre-seeded the negative inputs (−125bps Medicaid, −$1 investment, MA exits) but withheld the figure, leaving the market to triangulate a high-$20s, flat-to-down year without confirmation.
- A floor on the "at least 125bps" Medicaid decline. Asked directly to bound the downside, management declined — "at least" is open-ended, and the refusal to set a goalpost keeps tail risk live.
- The clean ~$5 Q3 number up front. Management led with the $6.03 reported figure and only disclosed the ~$1 below-the-line help and the $27 baseline in the prepared remarks — accurate, but presentation-managed.
- Its own ACA membership-loss estimate. Management cited CBO rather than putting an Elevance-specific number on the subsidy-cliff membership impact — a meaningful 2026 variable left unsized.
- Whether 2026 EPS grows or declines off $27. Stated only obliquely via "trough" and "2027 returns to balanced growth." The arithmetic points down, but management never said the word.
Market Reaction
- Pre-print setup: ELV closed at $354.07 on October 20, having rallied 12.9% over the trailing 30 days (off a September low near $313.71) as the group stabilized — but still down 4.0% YTD and down 16.1% over the trailing twelve months, deep within a wide $275–$497 52-week closing range.
- Reaction-day move: The stock gapped down 2.6% at the open ($344.70), traded an intraday range of $337.01–$354.58, and recovered to close at $349.75, down just 1.2% (−$4.32), on ~2.2x normal volume (4.1M vs. a 1.9M 30-day average). The S&P 500 closed flat, so the modest decline was idiosyncratic but minor.
- Where it sits: The $349.75 close left ELV at roughly 13x the $27 clean baseline (≈11.7x the headline $30) — a multiple that has begun to recover from the July trough as the reset proved durable.
The muted reaction is the most informative part of the tape. After the 12% July collapse and a sharp September-October recovery rally, a quarter that (a) reaffirmed rather than cut, (b) beat on low-quality below-the-line items, and (c) pre-framed 2026 as a down/trough year netted to a 1.2% fade — the market treating the print as "no new bad news" rather than "good news." That is consistent with a stock that has found a near-term floor on the de-rating but lacks a catalyst to re-rate higher until the trough is quantified and proven. The easy oversold bounce is behind it; the next leg requires January guidance the market can trust.
Street Perspective
Debate: Is the reaffirmed $30 a clean hold or propped up by below-the-line items?
Bull view: The reaffirm is the inflection that matters — the first quarter without a cut breaks the negative-revision streak and the in-line MLR shows the cost line is finally behaving; the $27 disclosure is just conservatism.
Bear view: A "beat" that leans ~$1 on tax timing and investment gains, with the company itself flagging a $27 clean base, is a quarter that operationally only met a previously-slashed bar — the headline flatters a still-deteriorating book.
Our take: Both are true; the reaffirm is genuinely important (third cut avoided), but the operating quarter was in line, not strong. The honest read is "stabilizing, not recovering" — which is a reason to stop selling, not yet a reason to buy.
Debate: Is 2026 really "the trough," or does OBBBA/subsidy expiry push the bottom into 2027?
Bull view: Planning 2026 off the Q4 exit rate is methodologically conservative, the OBBBA hit is <20% of members and staggered, and the four recovery levers are already in flight — 2026 is a datable bottom and 2027 inflects up.
Bear view: The same team called troughs in 2024 and 2025 that proved premature; with subsidy policy unresolved and a fresh OBBBA acuity shift landing late-2026 into 2027, the bottom could slip a year and "balanced 2027 growth" could become "another reset 2027."
Our take: The conservative Q4-exit anchoring and the <20%/staggered OBBBA sizing tilt us toward crediting the trough framing — but only tentatively. We need the January guide to convert the verbal trough into a number before underwriting it.
Debate: Valuation — does the de-rated multiple plus "2027 recovery" make this an early-entry Outperform?
Bull view: At ~13x a conservative $27 base, with a Stars-driven MA tailwind, a fast-growing Carelon, and a credible 2027 recovery, the patient buyer is being paid to own the trough before the re-rate.
Bear view: Buying ahead of a down 2026 with an unquantified guide and a live ACA policy binary is paying a full-ish multiple for a falling near-term number — the classic "too early" trap.
Our take: The recovery setup is real and we are constructive on the eventual re-rate, but the absence of a January guide and the live subsidy binary mean the risk/reward does not yet favor stepping in ahead of the print. A Hold with an explicit upgrade trigger — a credible, achievable 2026 guide — is the disciplined posture.
Model Update Needed
| Item | Prior Assumption | Updated | Reason |
|---|---|---|---|
| FY2025 Adjusted EPS | ~$30 | ~$30 (clean base $27) | Reaffirmed; ~$3 nonrecurring disclosed |
| FY2025 Medicaid operating margin | Positive, below target | ~−50bps (loss-making) | Acuity/utilization not offset by rates |
| FY2026 Adjusted EPS | ~$30–33 (wide) | ~high-$20s (flat-to-down off $27) | Medicaid −125bps + ~$1 investment − partial offsets |
| FY2026 framing | Unknown | "The trough" | Mgmt explicit; 2027 = recovery |
| Buyback | Ramping | $875M/Q pace | Confidence restored; M&A paused |
| MA Stars (PY2027) | — | ~55% in 4-star+ (vs ~40% PY2026) | 2027 rebate/bonus tailwind |
Valuation framework: We hold a fair-value range of roughly $330–$375, equivalent to ~12–13x a normalized ~$28–30 earnings power that blends the $27 clean 2025 base with the 2027 recovery trajectory. Against the $349.75 close, the midpoint (~$352) sits essentially at spot, implying minimal near-term upside — the textbook definition of a Hold. The asymmetry has narrowed since July: downside is better-protected now that the reset has held (a third cut is the main bear tail), while the upside (a re-rate toward the mid-teens multiple ELV historically commanded) requires a trusted 2026 guide and visible Medicaid inflection. We want the January catalyst before paying for the recovery.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: Carelon flywheel offsets health-plan cyclicality | Confirmed | Rx +20%, Services +50%, external revenue double-digit; engine intact |
| Bull #2: MA discipline + Stars step-up is a 2027 tailwind | Confirmed | Margin improving in 2025; ~55% in 4-star+ for PY2027 |
| Bull #3: The reset is durable (no more cuts) | Confirmed (this quarter) | ~$30 reaffirmed; in-line MLR — first non-negative surprise |
| Bull #4: 2026 is a datable trough before a 2027 recovery | Neutral / unproven | Methodologically conservative framing, but a forecast not a result |
| Bear #1: Medicaid is now loss-making and deepening into 2026 | Confirmed (bear) | ~−50bps FY2025; ≥125bps further decline planned for 2026 |
| Bear #2: 2026 carries a self-inflicted ~$1 investment drag | Confirmed (bear) | On top of the Medicaid trough; 2026 likely down off $27 |
| Bear #3: ACA subsidy cliff is an unsized 2026 binary | Confirmed (bear) | Material contraction risk; company won't size its own book |
Overall: Thesis unchanged — stabilizing franchise, un-underwritable near-term earnings. The good news (reset held, levers working) and the bad news (Medicaid loss-making, 2026 a trough) roughly offset, leaving the risk/reward balanced.
Action: Maintain Hold. The upgrade trigger is explicit: a January 2026 guide that is both credible and achievable, paired with evidence the Medicaid Q4 exit rate is the genuine bottom. Absent that, we are paid to wait, not to anticipate. A renewed downside surprise (a fourth effective cut via a worse-than-trough 2026 guide) would force a structural-impairment reassessment.